Anti-Human IL-1 beta/IL-1F2 Reference Antibody (Gevokizumab, RUO)
Anti-Human IL-1 beta/IL-1F2 Reference Antibody (Gevokizumab, RUO)  Anti-Human IL-1 beta/IL-1F2 Reference Antibody (Gevokizumab, RUO) 

Anti-Human IL-1 beta/IL-1F2 Reference Antibody (Gevokizumab, RUO)

  • Catalog number: BS10002
  • Availability: In Stock
  • $176.00

  • Ex Tax: $176.00


Available Options

Qty
Description: Research Grade Gevokizumab (BS10002) is a humanized monoclonal antibody detecting Interleukin-1 beta in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights:
• Multi-Application — Validated across multiple applications.
Host species: Humanized
Isotype: IgG2-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1.31mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Interleukin-1 beta, IL1B, Catabolin, IL1F2, IL-1beta
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: XOMA052, CAS:1129435-60-4
Background: Interleukin-1 beta (Interleukin-1 beta,IL1B,Catabolin,IL1F2,IL-1 beta) is a ~30 kDa protein. Potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells. Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6.
References:
1. Tominaga, K. et al. (2000) International immunology 12, 151-60. PMID: 1065385
2. Nakahara, H. et al. (2003) Arthritis and rheumatism 48, 1521-9. PMID: 12794819
3. LaRock, CN. et al. (2016) Science immunology 1. PMID: 28331908
4. Van Damme, J. et al. (1985) Nature 314, 266-8. PMID: 3920526
5. Tian, XX. et al. (2021) International endodontic journal 54, 916-925. PMID: 33377178
6. Xia, S. et al. (2021) Nature 593, 607-611. PMID: 33883744
Note: For research use only. Not suitable for clinical or therapeutic use.

Images

  • Bioactivity for Anti-Human IL-1 beta/IL-1F2 Reference Antibody (Gevokizumab, RUO)
    Bioactivity

    Detects Human IL1B/IL1F2 in indirect ELISAs.

  • SDS-PAGE for Anti-Human IL-1 beta/IL-1F2 Reference Antibody (Gevokizumab, RUO)
    SDS-PAGE

    SDS-PAGE for Research Grade Gevokizumab.

  • Western blot for Anti-Human IL-1 beta/IL-1F2 Reference Antibody (Gevokizumab, RUO)
    Western blot

    Western blot analysis was performed using anti-IL1B/IL1F2 monoclonal antibody at 1μg/ml on various samples.
    Lane 1: recombinant human IL1B/IL1F2 (Catalog No: PH10445), 50ng
    Lane 2: recombinant human IL1B/IL1F2 (Catalog No: PH10445), 30ng
    Lane 3: recombinant human IL1B/IL1F2 (Catalog No: PH10445), 20ng
    Lane 4: recombinant human IL1B/IL1F2 (Catalog No: PH10445), 10ng

Be the first to write a review for this product.

Write a review

Note: HTML is not translated!
Bad           Good